Telesis Bio, Inc (TBIO) Long-Term Debt to Capital Ratio

This chart illustrating the price evolution of Telesis Bio, Inc. (TBIO) demonstrates the asset's dynamics, with a value of 3.15. High production costs resulting from a small number of installed systems are currently capping growth. However, the integration of BioXp software and hardware creates a closed ecosystem for researchers, while equipment sales guarantee a steady stream of revenue from the sale of consumables and specialized cartridges.

Sales of Telesis Bio (TBIO) gene synthesis systems generate the current cash flow necessary for development. This metric correlates liabilities with a term of more than one year against equity to determine financial autonomy. This allows for an assessment of the business's ability to withstand shocks without the risk of default. A low value confirms a margin of safety for future licensing deals. By analyzing the long-term debt-to-equity trend, an investor can see the balance between leverage and stability.